Eli Lilly Net Total Equity Issued/Repurchased 2010-2024 | LLY
Eli Lilly annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2024. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- Eli Lilly net total equity issued/repurchased for the quarter ending December 31, 2024 was $-2.500B, a 233.33% increase year-over-year.
- Eli Lilly net total equity issued/repurchased for the twelve months ending December 31, 2024 was $-2.946B, a 1.8% decline year-over-year.
- Eli Lilly annual net total equity issued/repurchased for 2024 was $-2.5B, a 233.33% increase from 2023.
- Eli Lilly annual net total equity issued/repurchased for 2023 was $-0.75B, a 50% decline from 2022.
- Eli Lilly annual net total equity issued/repurchased for 2022 was $-1.5B, a 20% increase from 2021.
Eli Lilly Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$-2,500 |
| 2023 |
$-750 |
| 2022 |
$-1,500 |
| 2021 |
$-1,250 |
| 2020 |
$-500 |
| 2019 |
$-4,400 |
| 2018 |
$-2,491 |
| 2017 |
$-300 |
| 2016 |
$-600 |
| 2015 |
$-750 |
| 2014 |
$-800 |
| 2013 |
$-1,698 |
| 2012 |
$-721 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$717.806B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
